tumor specific new boron agent for BNCT

2014 Fiscal Year Final Research Report

• Project/Area Number: 24390293
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: Radiation science
• Research Institution: Okayama University
• Principal Investigator: MATSUI Hideki 岡山大学, 医歯(薬)学総合研究科, 教授 (30157234)
• Co-Investigator(Kenkyū-buntansha): MICHIUE Hiroyuki 岡山大学, 大学院医歯薬学総合研究科, 助教 (20572499)
• Co-Investigator(Renkei-kenkyūsha): ONO Koji 京都大学, 原子炉実験所中性子医療高度化研究部門, 教授 (90122407) ; MIYATAKE Shin-ichi 大阪医科大学, 先端医療開発部門, 教授 (90209916)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: がん / ホウ素中性子捕捉療法 / 粒子線治療 / 悪性脳腫瘍 / ホウ素薬剤研究 / 細胞内導入

Outline of Final Research Achievements

New anti-cancer therapy with boron neutron capture therapy (BNCT) is based on the nuclear reaction of boron-10 with neutron irradiation. In BNCT clinical trial, two boron compounds, BPA (boronophenylalanine) and BSH (sodium borocaptate), were used for BNCT. BPA is taken up into cells through amino acid transporters that are expressed highly in almost all malignant cells, but BSH cannot pass through the cell membrane and remains outside the cell. To overcome this disadvantage of BSH in BNCT, we used a cell-penetrating peptide system for transduction of BSH. CPP (cell-membrane penetrating peptide) is very common peptide domains that transduce many physiologically active substances into cells in vitro and in vivo. BSH-fused CPPs can penetrate the cell membrane and localize inside a cell. BSH-CPP is one of the most promising boron agent in next generation BNCT.

Free Research Field

癌